Parexel has named two new senior VPs within its clinical research services unit.
Dr Roland Andersson (pictured) joins the contract research organisation (CRO) from consultancy Accenture where he was managing director, while Dr Thomas Senderovitz joins from German pharma company Grunenthal, where he was executive VP of global compound development.
At Parexel the two new recruits will be involved in developing and implementing its global corporate objectives backed by a broad experience of the life sciences industry.
Dr Andersson’s specific responsibilities include managing client relationships for phase II and phase III programmes on a global basis.
This follows on from his role at Accenture where he oversaw technology, consulting and business services for leading pharma and biotech companies. At Accenture, he was vital in the creation of TransCelerate BioPharma, an industry group that aligns companies to address common drug development problems
Dr Senderovitz will have responsibility for the management of Parexel’s early phase and clinical logistics business units, as well as the global medical services function.
His past experience at Grunenthal includes providing strategic development and project oversight for all clinical development functions, including early clinical development, late stage clinical development, global clinical operations and global biometrics.
Prior to joining Grunenthal Dr Senderovitz served as VP of global exploratory development at UCB and VP of clinical R&D at Ferring Pharmaceuticals.